JP6216371B2 - ＹｅｒｓｉｎｉａｐｅｓｔｉｓＦ１−Ｖ融合タンパク質を発現するＳａｌｍｏｎｅｌｌａＴｙｐｈｉＴｙ２１ａおよびその使用 - Google Patents

ＹｅｒｓｉｎｉａｐｅｓｔｉｓＦ１−Ｖ融合タンパク質を発現するＳａｌｍｏｎｅｌｌａＴｙｐｈｉＴｙ２１ａおよびその使用 Download PDF

Info

Publication number
JP6216371B2
JP6216371B2 JP2015514155A JP2015514155A JP6216371B2 JP 6216371 B2 JP6216371 B2 JP 6216371B2 JP 2015514155 A JP2015514155 A JP 2015514155A JP 2015514155 A JP2015514155 A JP 2015514155A JP 6216371 B2 JP6216371 B2 JP 6216371B2
Authority
JP
Japan
Prior art keywords
plasmid
salmonella typhi
nucleic acid
plague
typhi ty21a
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015514155A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015519061A5 (enExample
JP2015519061A (ja
Inventor
デニス ジェイ． コペッコ，
デニス ジェイ． コペッコ，
マニュエル オソリオ，
マニュエル オソリオ，
モニカ アール． フット，
モニカ アール． フット，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of JP2015519061A publication Critical patent/JP2015519061A/ja
Publication of JP2015519061A5 publication Critical patent/JP2015519061A5/ja
Application granted granted Critical
Publication of JP6216371B2 publication Critical patent/JP6216371B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0291—Yersinia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
JP2015514155A 2012-05-23 2013-05-22 ＹｅｒｓｉｎｉａｐｅｓｔｉｓＦ１−Ｖ融合タンパク質を発現するＳａｌｍｏｎｅｌｌａＴｙｐｈｉＴｙ２１ａおよびその使用 Expired - Fee Related JP6216371B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261650676P 2012-05-23 2012-05-23
US61/650,676 2012-05-23
PCT/US2013/042240 WO2013177291A1 (en) 2012-05-23 2013-05-22 Salmonella typhi ty21a expressing yersinia pestis f1-v fusion protein and uses thereof

Publications (3)

Publication Number Publication Date
JP2015519061A JP2015519061A (ja) 2015-07-09
JP2015519061A5 JP2015519061A5 (enExample) 2016-06-09
JP6216371B2 true JP6216371B2 (ja) 2017-10-18

Family

ID=48539444

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015514155A Expired - Fee Related JP6216371B2 (ja) 2012-05-23 2013-05-22 ＹｅｒｓｉｎｉａｐｅｓｔｉｓＦ１−Ｖ融合タンパク質を発現するＳａｌｍｏｎｅｌｌａＴｙｐｈｉＴｙ２１ａおよびその使用

Country Status (7)

Country Link
US (1) US9409956B2 (enExample)
EP (1) EP2852405B1 (enExample)
JP (1) JP6216371B2 (enExample)
CN (1) CN104470537B (enExample)
IL (1) IL235615A0 (enExample)
IN (1) IN2014DN09618A (enExample)
WO (1) WO2013177291A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10806778B2 (en) * 2019-01-30 2020-10-20 Prokarium Limited Modified strain of Salmonella enterica Typhi

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3856935A (en) 1971-04-29 1974-12-24 Schweiz Serum & Impfinst Oral typhoid vaccine and method of preparing the same
GB9326425D0 (en) 1993-12-24 1994-02-23 Secr Defence Vaccine compositions
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
DE69535036T3 (de) 1994-07-15 2011-07-07 The University of Iowa Research Foundation, IA Immunomodulatorische oligonukleotide
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
WO1996028551A1 (en) 1995-03-13 1996-09-19 The Secretary Of State For Defence Vaccines for plague
AU738513B2 (en) 1997-02-28 2001-09-20 University Of Iowa Research Foundation, The Use of nucleic acids containing unmethylated CpG dinucleotide in the treatment of LPS-associated disorders
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP1003531B1 (en) 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
EP1067956B1 (en) 1998-04-03 2007-03-14 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
DK1108034T3 (da) * 1998-09-04 2008-11-10 Emergent Product Dev Uk Ltd Svækkede salmonella SPI2-mutanter som antigenbærere
GB9921275D0 (en) * 1999-09-10 1999-11-10 Secr Defence Recombinant microorganisms
EP1670505B1 (en) 2003-09-18 2012-11-14 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Dna promoters and anthrax vaccines
US20070087013A1 (en) * 2003-12-09 2007-04-19 Donata Sizemore Orally-administered live bacterial vaccines for plague
US20080124355A1 (en) * 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
EP1921149A1 (en) * 2006-11-13 2008-05-14 AEterna Zentaris GmbH Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof

Also Published As

Publication number Publication date
CN104470537A (zh) 2015-03-25
IN2014DN09618A (enExample) 2015-07-31
CN104470537B (zh) 2017-04-26
US20150152144A1 (en) 2015-06-04
EP2852405A1 (en) 2015-04-01
US9409956B2 (en) 2016-08-09
WO2013177291A8 (en) 2014-12-24
IL235615A0 (en) 2015-01-29
EP2852405B1 (en) 2019-03-13
WO2013177291A1 (en) 2013-11-28
JP2015519061A (ja) 2015-07-09

Similar Documents

Publication Publication Date Title
Wang et al. Lactic acid bacteria as mucosal delivery vehicles: a realistic therapeutic option
Pasquevich et al. The protein moiety of Brucella abortus outer membrane protein 16 is a new bacterial pathogen-associated molecular pattern that activates dendritic cells in vivo, induces a Th1 immune response, and is a promising self-adjuvanting vaccine against systemic and oral acquired brucellosis
Tarahomjoo Development of vaccine delivery vehicles based on lactic acid bacteria
JP5245092B2 (ja) 百日咳に対する単一用量ワクチンとしての生弱毒化ボルデテラ株
Yunle et al. Advances in Helicobacter pylori vaccine research: From candidate antigens to adjuvants—A review
CN103304670B (zh) 结核分枝杆菌特异性融合蛋白疫苗ab及其制备和应用
JP2012501959A (ja) Ｙｅｒｓｉｎｉａｐｅｓｔｉｓ抗原を含む組成物
DK2525817T3 (en) Vaccine vectors and methods for enhancing immune responses
US12370248B2 (en) Attenuated salmonella synthesizing antigens for vaccinating against helicobacter pylori
JP2016515133A (ja) 腸内病原体の免疫応答を強化する組成物及び方法
JP6195089B2 (ja) ストレプトコッカス・ニューモニエによる肺炎に対するキメラタンパク質ワクチン
JP2023503057A (ja) ヘモフィルス・パラスイスに対する新規ワクチン
JP2023503058A (ja) ヘモフィルス・パラスイスに対する新規ワクチン
JP2020529408A (ja) ストレプトコッカス・スイスに対する防御のためのワクチン
CN1437479B (zh) 重组胞内病原体疫苗和使用方法
US20090324638A1 (en) Live bacterial vaccine
KR101743442B1 (ko) 장독소성 대장균 항원을 발현하는 고스트 살모넬라 변이주를 유효성분으로 포함하는 돼지 부종병의 예방 또는 치료용 백신 조성물
ES2655421T3 (es) Vacuna contra la peste
JP6216371B2 (ja) ＹｅｒｓｉｎｉａｐｅｓｔｉｓＦ１−Ｖ融合タンパク質を発現するＳａｌｍｏｎｅｌｌａＴｙｐｈｉＴｙ２１ａおよびその使用
JP6401148B2 (ja) 抗原および抗原の組み合わせ
US20240299528A1 (en) A dna plasmid sars-corona virus-2/covid-19 vaccine
RU2701733C1 (ru) Живая вакцина на основе штамма пробиотиков ENTEROCOCCUS FAECIUM L3 для профилактики инфекции, вызванной STREPTOCOCCUS PNEUMONIE
Ehteshaminia et al. Next-generation pertussis vaccines with special focus on intranasal vaccination
US20150238590A1 (en) Use of the salmonella spp type iii secretion proteins as a protective vaccination
US20130149330A1 (en) Pharmaceutical compositions and methods of blocking bacillus anthracis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160415

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160415

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170120

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170418

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170620

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170829

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170922

R150 Certificate of patent or registration of utility model

Ref document number: 6216371

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees